STOCK TITAN

Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cogent Biosciences (Nasdaq: COGT), a biotechnology firm focused on precision therapies for genetically defined diseases, will present at the Wedbush PacGrow Healthcare Conference on August 10, 2021, from 10:55 to 11:25 AM ET. CEO Andrew Robbins will lead the presentation. Attendees can access the live webcast and archived recording via the Cogent Biosciences investor relations website.

Cogent's lead therapy, bezuclastinib, targets KIT mutations linked to systemic mastocytosis and gastrointestinal stromal tumors.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass. and BOULDER, Colo., July 27, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, from 10:55 -11:25am ET.

Access to the webcast of this event, as well as an archived recording, will be available under the "Events" tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events.

About Cogent Biosciences, Inc. 
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the newly formed Cogent Research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, Co. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cogent-biosciences-to-present-at-wedbush-pacgrow-virtual-healthcare-conference-2021-301341731.html

SOURCE Cogent Biosciences, Inc.

FAQ

When is Cogent Biosciences presenting at the Wedbush PacGrow Healthcare Conference?

Cogent Biosciences will present on August 10, 2021, from 10:55 to 11:25 AM ET.

Who is presenting for Cogent Biosciences at the conference?

CEO Andrew Robbins will present at the Wedbush PacGrow Healthcare Conference.

Where can I watch the Cogent Biosciences conference presentation?

The presentation will be available via webcast and archived on the Cogent Biosciences investor relations website.

What is the focus of Cogent Biosciences?

Cogent Biosciences focuses on developing precision therapies for genetically defined diseases.

What is bezuclastinib and its significance?

Bezuclastinib is Cogent's lead therapy targeting the KIT D816V mutation linked to serious conditions like systemic mastocytosis.

Cogent Biosciences, Inc.

NASDAQ:COGT

COGT Rankings

COGT Latest News

COGT Stock Data

879.28M
109.39M
0.12%
111.16%
6.99%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM